Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Dec 14;114(4):1324–1336. doi: 10.1111/cas.15676

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2022 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association.

This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.

PMC Copyright notice

ScRNA‐seq analysis comparing control (DMSO) and D1 inhibitor (SKF‐83566 4 μM) treatment. (A) Heatmap visualization of the 50 most frequently appearing upregulated genes in D1 inhibitor‐treated Sph18‐16 sample by enrichment analysis using all GOBP terms. The details are provided in Table S5. (B) Violin plots depicting the expression of genes compared with control (red) and D1 inhibitor‐treated sample (green). Bar indicates the median value. Adjusted p‐value for B1 of WNT7A, 0.00058; B1 of WNT7B, 0.0029; INT1 of WNT7B, 0.0013; B1 of DKK1, 0.0018. (C) Proliferating cells of each cluster in control or D1 inhibitor‐treated sample (top). Listed percentages of cells in S and G2/M phases of each cluster (down). (D) Trajectories showing INT1 as the center in DMSO and INT2 in D1 inhibitor treatment